Huaban Tongmai decoction attenuates ferroptosis-associated vascular inflammation in carotid artery atherosclerosis with involvement of the p53-Parkin mitophagy pathway
- 1Hospital of Chengdu University of Traditional Chinese Medicine, Sichuan, China
- 2Chengdu University of Traditional Chinese Medicine, Sichuan, China
Abstract
BackgroundCarotid artery atherosclerosis (CAS) is a chronic inflammatory vascular disease in which ferroptosis—an iron-dependent, oxidative form of regulated cell death—has been implicated in endothelial injury and vascular inflammatory responses. Despite growing evidence for the therapeutic potential of Huaban Tongmai decoction (HBTMD) against CAS, existing studies have not clearly elucidated its specific molecular mechanisms. This study focused on exploring and elucidating the mitigating mechanism of HBTMD against CAS.MethodsAn in vivo ApoE-/- mouse model of CAS was constructed via high-fat diet (HFD) combined with carotid ligation, and an ox-LDL-induced endothelial injury model using human umbilical vein endothelial cells (HUVECs). The chemical components of HBTMD were screened by UHPLC-MS/MS, and its marker constituents were quantified. Integrative proteomics and untargeted metabolomics identified key DEPs and metabolites related to HBTMD intervention. Network pharmacology, molecular docking, and molecular dynamics simulations explored potential molecular interactions and candidate targets. Ferrostatin-1 (Fer-1), Mdivi-1, and p53 siRNA were used in the indicated cell experiments to explore ferroptosis-associated injury and possible mitochondrial regulatory mechanisms.ResultsUHPLC-MS/MS identified 684 chemical constituents in HBTMD. Pharmacodynamic evaluation showed that HBTMD significantly reduced carotid lipid accumulation and plaque area in CAS mice. Integrated proteomic and metabolomic analyses suggested that modulation of autophagy and ferroptosis pathways may underlie HBTMD’s efficacy. Network pharmacology predicted p53 as a core target. Molecular docking and MD simulations suggested plausible interactions of spinosin and salvianolic acid A with p53, without establishing direct target engagement. In vitro and in vivo validation showed that HBTMD improved mitochondrial integrity, reduced inflammatory cytokines, and inhibited ferroptosis. HBTMD also lowered ROS and altered markers consistent with increased mitophagy-related activity; Mdivi-1 partially attenuated selected protective effects. The additional effects of HBTMD on several pathway-associated proteins were diminished after p53 knockdown, supporting the involvement of p53 but not establishing a complete causal pathway.ConclusionThese preclinical findings suggest that HBTMD attenuates ferroptosis-associated endothelial injury and vascular inflammation in experimental CAS, accompanied by changes in p53-Parkin signaling and mitophagy-related markers. The pathway warrants further causal and translational validation.
Related
- ATP6V0D2 Promotes Atherosclerosis‐Associated Vascular Smooth Muscle Cell Dysfunction by Modulating Ferroptosis‐Related Signaling
- circCRIM1 inhibits endothelial cell ferroptosis in atherosclerosis via regulating miR-567/PRDX3 pathway
- Ginsenoside Rd alleviates atherosclerosis by inhibiting adipocyte ferroptosis in perivascular adipose tissues
- Dihydrotanshinone I Attenuates Atherosclerosis via Inhibiting NLRP3 Inflammasome Activation and Modulating Gut Microbiota
- Ellagic Acid Attenuates High-Fat, High-Sucrose Diet-Induced Cardiac Fibrosis by Suppressing AGE–RAGE Signaling, Oxidative Stress, and Inflammation
BibTeX
@article{zou2026huaban,
title = {{Huaban Tongmai decoction attenuates ferroptosis-associated vascular inflammation in carotid artery atherosclerosis with involvement of the p53-Parkin mitophagy pathway}},
author = {Jiaxi Zou and Jiaxi Zou and Xiujuan Zhou and Xiujuan Zhou and Ni Jin and Mei Lai and Liying He and Liying He and Peiyang Gao},
journal = {Frontiers in Cell and Developmental Biology},
year = {2026},
month = nov,
doi = {10.3389/fcell.2026.1968603},
url = {https://doi.org/10.3389/fcell.2026.1968603},
note = {CC BY},
}
RIS
TY - JOUR
TI - Huaban Tongmai decoction attenuates ferroptosis-associated vascular inflammation in carotid artery atherosclerosis with involvement of the p53-Parkin mitophagy pathway
AU - Jiaxi Zou
AU - Jiaxi Zou
AU - Xiujuan Zhou
AU - Xiujuan Zhou
AU - Ni Jin
AU - Mei Lai
AU - Liying He
AU - Liying He
AU - Peiyang Gao
PY - 2026
DA - 2026/11/06
JO - Frontiers in Cell and Developmental Biology
DO - 10.3389/fcell.2026.1968603
UR - https://doi.org/10.3389/fcell.2026.1968603
AB - BackgroundCarotid artery atherosclerosis (CAS) is a chronic inflammatory vascular disease in which ferroptosis—an iron-dependent, oxidative form of regulated cell death—has been implicated in endothelial injury and vascular inflammatory responses. Despite growing evidence for the therapeutic potential of Huaban Tongmai decoction (HBTMD) against CAS, existing studies have not clearly elucidated its specific molecular mechanisms. This study focused on exploring and elucidating the mitigating mechanism of HBTMD against CAS.MethodsAn in vivo ApoE-/- mouse model of CAS was constructed via high-fat diet (HFD) combined with carotid ligation, and an ox-LDL-induced endothelial injury model using human umbilical vein endothelial cells (HUVECs). The chemical components of HBTMD were screened by UHPLC-MS/MS, and its marker constituents were quantified. Integrative proteomics and untargeted metabolomics identified key DEPs and metabolites related to HBTMD intervention. Network pharmacology, molecular docking, and molecular dynamics simulations explored potential molecular interactions and candidate targets. Ferrostatin-1 (Fer-1), Mdivi-1, and p53 siRNA were used in the indicated cell experiments to explore ferroptosis-associated injury and possible mitochondrial regulatory mechanisms.ResultsUHPLC-MS/MS identified 684 chemical constituents in HBTMD. Pharmacodynamic evaluation showed that HBTMD significantly reduced carotid lipid accumulation and plaque area in CAS mice. Integrated proteomic and metabolomic analyses suggested that modulation of autophagy and ferroptosis pathways may underlie HBTMD’s efficacy. Network pharmacology predicted p53 as a core target. Molecular docking and MD simulations suggested plausible interactions of spinosin and salvianolic acid A with p53, without establishing direct target engagement. In vitro and in vivo validation showed that HBTMD improved mitochondrial integrity, reduced inflammatory cytokines, and inhibited ferroptosis. HBTMD also lowered ROS and altered markers consistent with increased mitophagy-related activity; Mdivi-1 partially attenuated selected protective effects. The additional effects of HBTMD on several pathway-associated proteins were diminished after p53 knockdown, supporting the involvement of p53 but not establishing a complete causal pathway.ConclusionThese preclinical findings suggest that HBTMD attenuates ferroptosis-associated endothelial injury and vascular inflammation in experimental CAS, accompanied by changes in p53-Parkin signaling and mitophagy-related markers. The pathway warrants further causal and translational validation.
SN - 2296-634X
ER -